Printed from Voxsanity (voxsanity.com.au) — NCT07567326 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Lung Cancer
Phase 2 Lung Cancer Trial, Not Yet Recruiting
NCT07567326
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People aged between 18 and 75 years old.
- People who have been diagnosed with a specific type of lung cancer called non-small cell lung cancer (NSCLC) at stage II, IIIA, or a selected form of stage IIIB, confirmed through a tissue or cell sample, where the treating doctor considers the tumour suitable for surgical removal with the aim of curing the disease.
- People who are able to provide a tumour tissue sample, either one previously collected or a new one taken before the study begins.
- People who have measurable areas of cancer visible on a CT or MRI scan (assessed within 28 days before the study starts), meeting specific measurement standards used in cancer research.
- People whose general health and ability to carry out daily activities is rated at 0 or 1 on a standard medical scale (meaning fully active or able to carry out light activities).
- People who have not previously received any treatment for their cancer, including radiation, chemotherapy, surgery, or targeted therapy.
- People whose blood counts and organ function (such as liver and kidneys) meet the required health levels for the study.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People whose lung cancer has been confirmed as small cell lung cancer (SCLC), a mix of SCLC and NSCLC, or another type that is not NSCLC.
- People whose cancer has specific gene changes (known as EGFR mutations, ALK positivity, or other similar driver mutations) for which approved targeted treatments are available.
- People who have fluid around the lungs that contains cancer cells (malignant pleural effusion); people found to have drainable fluid around the lungs during screening must have it tested to rule out cancer cells being present.
- People who have previously received systemic (whole-body) cancer treatment for NSCLC; people who have used traditional Chinese medicine (TCM) as an anti-cancer treatment may only be considered if at least 2 weeks have passed since completing that therapy before the study begins.
- People who have received whole-body immune-suppressing medication within 2 weeks before the study starts, or who are expected to need such medication during the study.
- People who are currently taking part in another interventional clinical trial, or who have received another experimental drug or device within 4 weeks before the study starts.
- People who have had a different type of cancer (other than NSCLC) within the past 5 years before joining.
- People who have an autoimmune disease.
- People with known or suspected lung scarring or inflammation conditions (such as idiopathic pulmonary fibrosis or organising pneumonia), or other moderate to severe lung diseases that could interfere with detecting or managing lung side effects from the study drug, or that significantly affect breathing.
- People with serious heart or blood vessel conditions, or those who have had significant bleeding or a clear tendency to bleed within 1 month before the study starts.
- People who have had a blood clot in a vein or artery (such as a deep vein thrombosis or pulmonary embolism) within 3 months before the study starts.
- People with inherited or acquired immune system deficiencies, including HIV infection, active hepatitis B, or hepatitis C.
- People who have had an active tuberculosis infection within 1 year before the study starts.
- People who have had a serious infection within 4 weeks before the study starts.
- People who have received a live vaccine within 28 days before the study starts, or who plan to receive one during the study.
- People who have had major surgery (not including diagnostic procedures or biopsies) within 28 days before the study starts.
- People who have previously had, or are planning to have, a bone marrow transplant or solid organ transplant from a donor.
- People who have had a severe allergic reaction to a monoclonal antibody or fusion protein in the past, or who are known to be allergic to any ingredient in the assigned study treatment.
- Women who are pregnant, breastfeeding, or planning to become pregnant during the study period.
- People with a known history of substance misuse, alcohol misuse, or drug addiction.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Not Yet Recruiting
Phase
Phase 2
Sponsor
Peking University Cancer Hospital & Institute
Registry
ClinicalTrials.gov
Start date
1 July 2026
Est. completion
1 December 2028
Primary endpoints
pCR rate
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.